EHS
EHS

Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma



Affiliations

Item in Clipboard

Piotr Kuna et al.


Pharmacol Res Perspect.


2022 Aug.

Abstract

The single-inhaler extrafine formulation triple combination beclometasone dipropionate (BDP), formoterol fumarate (FF) plus glycopyrronium bromide (GB) is available for asthma management in adults. Its use in adolescents has not yet been evaluated. This study investigated the pharmacokinetic profile of BDP/FF/GB in adults and adolescents, with the aim of ruling out higher plasma exposure in adolescents compared to adults. In this open-label, non-randomized study, patients with asthma aged 12-17 (adolescents) and 18-64 years (adults) self-administered a single dose of BDP/FF/GB 400/24/50 μg via pressurized metered-dose inhaler (pMDI). The primary objective was to rule out higher systemic exposure to beclometasone 17-monopropionate (B17MP; active metabolite of BDP), formoterol, and GB in terms of the area under the plasma concentration-time curve from 0 to the last quantifiable concentration (AUC0-t ) in adolescents versus adults. A total of 40 adolescents and 40 adults entered the study (mean age of 14.8 and 43.6 years, respectively). The primary objective (AUC0-t ) was met, with the upper 90% confidence interval of the geometric mean ratio between adolescents and adults <125% for B17MP (point estimate 79.28 [90% CI 71.19; 88.29]), formoterol (88.68 [77.71; 101.20]) and GB (85.49 [72.96; 100.16]). All secondary pharmacokinetic endpoints supported the primary, with pharmacodynamic (safety) and tolerability results similar in the two populations. In conclusion, systemic exposure to extrafine BDP/FF/GB pMDI in adolescents was not higher than that in adults. Furthermore, there were no safety or tolerability signals to warrant a reduction in the dose of BDP/FF/GB for adolescents with asthma.


Keywords:

adolescents; asthma; pharmacodynamics; pharmacokinetics; systemic exposure; triple therapy.

References

REFERENCES

    1. Global Initiative For Asthma. Global Strategy for Asthma Management and Prevention. 2021. Accessed December 21, 2021. https://ginasthma.org/reports/

    1. Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394:1737-1749. doi:10.1016/S0140-6736(19)32215-9

    1. Cella M, Täubel J, Delestre-Levai I, Tulard A, Vele A, Georges G. Ethnic sensitivity study of the extrafine, single-inhaler, triple therapy beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide pressurized metered dose inhaler in Japanese and Caucasian healthy individuals: a randomized, double-bli. Clin Ther. 2021;43:P1934-P1947. doi:10.1016/j.clinthera.2021.09.001

    1. Hu C, Miao J, Shu S, Wang Y, Zhu X, Luo Z. Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects. Eur J Pharm Sci. 2020;144:105198. doi:10.1016/j.ejps.2019.105198

    1. European Medicines Agency. Guideline on the Investigation of Bioequivalence. 2010. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-in…



Source link

EHS
Back to top button